Interferon-α inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins

Cell Growth and Differentiation

Volumn 10, Issue 8, 1999, Pages 575-582

  Erickson, Sven ^a   Sangfelt, Olle ^a   Castro, Juan ^a   Heyman, Mats ^a   Einhorn, Stefan ^a   Grandér, Dan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL CYCLE PROTEIN; CYCLINE; INTERLEUKIN 2; PROTEIN P27; RECOMBINANT GAMMA INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

BLOTTING, NORTHERN; CDC25 PHOSPHATASE; CELL CYCLE; CELL CYCLE PROTEINS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICROTUBULE-ASSOCIATED PROTEINS; PHYTOHEMAGGLUTININS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; T-LYMPHOCYTES; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0032812664     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Altman, A., Coggeshall, K. M., and Mustelin, T. Molecular events mediating T cell activation. Adv. Immunol., 48: 227-360, 1990.
2. Taniguchi, T., and Minami, Y. The IL-2/IL-2 receptor system: a current overview. Cell, 73: 5-8, 1993.
3. Taniguchi, T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science (Washington DC), 268: 251-255, 1995.
4. Klimpel, G. R., Infante, A. J., Patterson, J., Hess, C. B., and Asuncion, M. Virus-induced interferon α/β (IFN-α/β) production by T cells and by Th1 and Th2 helper T cell clones: a study of the immunoregulatory actions of IFN-γ versus IFN-α/β on functions of different T-cell populations. Cell. Immunol., 128: 603-618, 1990.
5. Belardelli, F., and Gresser, I. The neglected role of type I Interferon in the T-cell response: implications for its clinical use. Immunol. Today, 17: 369-372, 1996.
6. Pines, J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J., 308: 697-711, 1995.
7. Graña, X., and Ready, E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211-219, 1995.
8. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massagué, J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potent mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
9. Coats S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
10. 1 Cdk-complex and activation of pocket proteins. Oncogene, 18: 2798-2810, 1999.
11. 1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
12. Polyak, K., Kato, J., Solomon, J. M., Sherr, C. J., Massagué, J., Roberts, J. M., and Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
13. Firpo, J. E., Koff, A., Solomon, M. J., and Roberts, J. M. Inactivation of a Cdk2 inhibitor during interteukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol., 14: 4889-4901, 1994.
14. Nourse, J., Firpo, E., Flanagan, M. W., Coats, S., Polyak, K., Lee, M. H., Massagué, J., Crabtree, G. R., and Roberts, J. M. Interteukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
15. 1 phase in primary human T lymphocytes. J. Biol. Chem., 268: 4113-4119, 1993.
16. Nelson, B. H., Lord, J. D., and Greenberg, P. D. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature (Lond.), 369: 333-336, 1994.
17. Nakamura, Y., Russell, S. M., Mess, S. A., Friedmann, M., Erdos, M., Francois, C., Jacques, Y., Adelstein, S., and Leonard, W. J. Heterodimerization of the IL-2 receptor β-and γ-chain cytoplasmic domains is required for signalling. Nature (Lond.), 369: 330-333, 1994.
18. Brennan, P., Babbage, J. W., Burgering, B. M. T., Groner, B., Reif, K., and Cantrell, D. A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity, 7: 679-689, 1997.
19. De Mayer, E., and De Mayer-Guiginard, E. Interferons and other regulatory cytokines. New York: John Wiley & Sons Inc., 1983.
20. Grandér, D., Sangfelt, O., and Erickson, S. How does interferon exert its cell growth inhibitory effect? Eur. J. Haematol., 59: 129-135, 1997.
21. Einhorn, S., and Strander, H. Interferon treatment of human malignancies: a short review. Med. Oncol. Tumor Pharmacother., 10: 25-29, 1993.
22. Sangfelt, O., Erickson, S., Einhorn, S., and Grandér, D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene, 14: 415-423, 1997.
23. 0-liKe arrest. Mol. Cell. Biol., 16: 3934-3944, 1996.
24. Erickson, S., Sangfelt, O., Heyman, M., Castro, J., Einhorn, S., and Grander, D. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene, 17: 595-602, 1998.
25. Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., and Bartek, J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev., 11: 1479-1492, 1997.
26. Gu, Y., Rosenblatt, J., and Morgan, D. O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J, 11: 3995-4005, 1992.
27. Moberg, K., Starz, M. A., and Lees, J. A. E2F-4 switches from p130 to p107 and pRb in response to cell cycle reentry. Mol. Cell. Biol., 16: 1436-1449, 1996.
28. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., and Fu, X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (Washington DC), 272: 719-722, 1996.
29. Weiss, A., and Imboden, J. B. Cell surface molecules and early events involved in human T lymphocyte activation. Adv. Immunol., 41: 1-38, 1987.
30. Aprelikova, O., Xiong, Y., and Lui, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem., 270: 18195-18197, 1995.
31. Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., and Clurman, B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev., 11: 1464-1478, 1997.
32. Songia, S., Mortellaro, A., Taverna, S., Fornasiero, C., Scheiber, E. A. Erba, E., Colotta, F., Mantovani, A., Isetta, A. M., and Golay, J. Characterization of the new immunosuppressive drug undeculprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent-4 as molecular targets. J. Immunol., 158: 3987-3995, 1997.
33. Uddin, S., Fish, E. N., Sher, D. A., Gardziola, C., White, M. F., and Platanias, L C. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-α. J. Immunol., 158: 2390-2397, 1997.
34. Pfeffer, L. M., Mullersman, J. E., Pfeffer, S. R., Murti, A., Shi, W., and Yang, C. M. STAT3 as an adapter to couple phosphatidylinositol 3-kinse to the IFNAR1 chain of the type I interferon receptor. Science (Washington DC), 276: 1418-1420, 1997.
35. Minami, Y., Nakagawa, Y., Kawahara, A., Miyazaki, T., Sada, K., Yamamura, H., and Taniguchi, T. Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway. Immunity, 2: 89-100, 1995.
36. Müller, D., Bouchard, C., Rudolph, B., Steiner, P., Stuckmann, I., Saffrich, R., Ansorge, W., Huttner, W., and Eilers, M. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene, 15: 2561-2576, 1997.
37. Ross C, Tingsgaard, P., Jorgensen, H., and Vejlsgaard, G. L. Interferon treatment of cutaneous T-cell lymphoma. Eur. J. Haematol., 57: 63-72, 1993.
38. Jacobs, L., and Johnson, K. P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 51: 1245-1252, 1994.
39. Strander, H. Toxicity of interferons. I. In: R. Stuart-Hall & H. D. Penny (eds.), The Clinical Applications of the Interferons, pp. 331-363. London: Chapman & Hall Medical, 1997.
40. Zhang, Q., Nowak, I., Vonderheid, E. C., Rook, A. H., Kadin, M. E., Nowell, P. C., Shaw, L M., and Wasik, M. A. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA, 93: 9148-9153, 1996.
41. Sangtelt, O., Erickson, S., Castro, J., Heiden, T., Einhorn, S., and Grandér, D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-α in hematopoietic cell lines. Cell Growth Differ., 8: 343-352, 1997.
42. Heiden, T., Gohde, W., and Tribukait, B. Two-wavelength mercury arc lamp excitation for flow cytometric DNA-protein analysis. Anticancer Res., 10: 1555-1562, 1990.